<DOC>
	<DOCNO>NCT02955147</DOCNO>
	<brief_summary>The purpose study determine whether ustekinumab effective treatment Giant Cell Arteritis ( GCA )</brief_summary>
	<brief_title>Ustekinumab Treatment Giant Cell Arteritis</brief_title>
	<detailed_description>The objective study evaluate efficacy safety ustekinumab , interleukin ( IL ) -12/23 inhibitor , patient GCA Hypothesis IL-12/23 pathway blockade may maintain disease remission patient GCA Specific Aims - To evaluate safety tolerability ustekinumab administration 20 patient GCA - To evaluate efficacy ustekinumab remission maintenance glucocorticoid spar 20 patient GCA</detailed_description>
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Subjects must meet follow criterion 1 . Able willing provide write informed consent comply study protocol 2 . Diagnosis GCA classify accord follow criterion : Age 50 year old History erythrosedimentation rate ( ESR ) ≥ 50 mm/hour Creactive protein ( CRP ) ≥ 10 mg/L AND least one following : Cranial symptom GCA Symptoms polymyalgia rheumatica ( PMR ) AND least one following : Temporal artery biopsy reveal feature GCA Evidence largevessel vasculitis angiography crosssectional imaging 3 . Active newonset relapse active disease 1 . Allergies : Subjects history previous severe allergic anaphylactic reaction associate administration monoclonal antibody antibody fragment . 2 . Systemic infection : Subjects active systemic infection . 3 . Serious infection : Subjects serious infection , major episode infection require hospitalization treatment IV antibiotic within 4 week enrollment . 4 . Chronic recurrent infection : Subjects chronic recurrent bacterial , viral , fungal , mycobacterial , protozoan infection . 5 . Opportunistic infection : Subjects , , opportunistic infection within 6 month prior enrollment . 6 . Subjects active hepatitis B active hepatitis C document history HIV 7 . Latent tuberculosis infection 8 . Malignancy 9 . Subjects evidence serious uncontrolled concomitant cardiovascular , nervous system , pulmonary , renal , hepatic , endocrine , immunologic , psychiatric gastrointestinal disease could interfere participation trial accord protocol . 10 . Subjects transplant organ ( exception corneal transplant &gt; 3 month prior screen ) 11 . Major surgery within 8 week prior Screening plan major surgery within 12 month Baseline 12 . Pregnancy 13 . The following laboratory abnormality Hemoglobin &lt; 8 gr/dL Platelets &lt; 100/mm3 White blood cell count ( WBC ) &lt; 3000/mm3 Absolute neutrophil count &lt; 2000/mm3 Absolute lymphocyte count &lt; 500/mm3 Serum creatinine &gt; 1.4 mg/dL female subject &gt; 1.6 mg/dL male subject Total bilirubin &gt; 2 mg/dL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5 X upper limit normal Positive hepatitis B surface antigen , hepatitis B core antibody hepatitis C antibody 14 . Prohibited medication : Subjects receive methotrexate ( MTX ) &gt; 30 mg weekly , azathioprine , mycophenolate mofetil , cyclophosphamide , chlorambucil , tacrolimus , leflunomide , canakinumab , belimumab , abatacept , tocilizumab , secukinumab , infliximab , etanercept , adalimumab , golimumab , certolizumab within 3month period prior enrollment . Subjects treatment anticluster designation antigen ( CD ) 20 agent ( e.g. , rituximab ) within 9month period prior enrolment Subjects use investigational drug within 1 month prior enrollment within 5 halflives investigational agent , whichever longer . Low dose MTX : Patients &lt; 30 mg MTX weekly eligible enrollment 2week washout interval receive ustekinumab Vaccines : Subjects receive live virus bacterial vaccination bacille CalmetteGuerin ( BCG ) within 3 month first administration study agent , expect receive live virus live bacterial vaccination study , 3 month last administration ustekinumab eligible . Subjects receive BCG vaccine within 12 month first administration study agent , expect receive BCG vaccine study , 12 month last administration ustekinumab also eligible .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>